Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 23551156)

1.

Commentary: vancomycin or metronidazole in patients with primary sclerosing cholangitis?

Paterson JC, Dillon JF.

Aliment Pharmacol Ther. 2013 May;37(9):915. doi: 10.1111/apt.12282. No abstract available.

PMID:
23551156
2.

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.

Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD.

Aliment Pharmacol Ther. 2013 Mar;37(6):604-12. doi: 10.1111/apt.12232. Epub 2013 Feb 5.

PMID:
23384404
3.

Primary sclerosing cholangitis: providing a safe and effective treatment.

Imam MH, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):255-7. doi: 10.1586/egh.12.11. No abstract available.

PMID:
22646247
4.

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21. No abstract available.

5.

Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.

Santander C, Moreno-Otero R.

Aliment Pharmacol Ther. 2012 Apr;35(7):846; discussion 847. doi: 10.1111/j.1365-2036.2012.05019.x. No abstract available.

PMID:
22404405
6.

Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.

Wenisch JM, Schmid D, Kuo HW, Allerberger F, Michl V, Tesik P, Tucek G, Laferl H, Wenisch C.

Antimicrob Agents Chemother. 2012 Apr;56(4):1974-8. doi: 10.1128/AAC.05647-11. Epub 2012 Jan 17.

7.

Comparative effectiveness of Clostridium difficile treatments: a systematic review.

Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, Wilt TJ.

Ann Intern Med. 2011 Dec 20;155(12):839-47. doi: 10.7326/0003-4819-155-12-201112200-00007. Review.

PMID:
22184691
8.

Medical and endoscopic therapy of primary sclerosing cholangitis.

Weismüller TJ, Lankisch TO.

Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):741-52. doi: 10.1016/j.bpg.2011.10.003. Review.

PMID:
22117639
9.

[Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis].

Strassburg CP, Manns MP.

Internist (Berl). 2011 Dec;52(12):1394-406. doi: 10.1007/s00108-011-2924-2. German.

PMID:
22086106
10.

Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.

Venugopal AA, Riederer K, Patel SM, Szpunar S, Jahamy H, Valenti S, Shemes SP, Khatib R, Johnson LB.

Scand J Infect Dis. 2012 Apr;44(4):243-9. doi: 10.3109/00365548.2011.631029. Epub 2011 Nov 13.

PMID:
22077148
11.

'Game changer' antibiotic and others in works for superbug.

Dolgin E.

Nat Med. 2011 Jan;17(1):10. doi: 10.1038/nm0111-10. No abstract available.

PMID:
21217660
12.

Secondary sclerosing cholangitis following major burn injury-An underestimated issue in burn care?

Ipaktchi R, Knobloch K, Vogt PM.

Burns. 2011 Mar;37(2):355-6; author reply 356-9. doi: 10.1016/j.burns.2010.06.014. Epub 2010 Oct 18. No abstract available.

PMID:
20961689
13.

Clostridium difficile bacteremia, Taiwan.

Lee NY, Huang YT, Hsueh PR, Ko WC.

Emerg Infect Dis. 2010 Aug;16(8):1204-10. doi: 10.3201/eid1608.100064. Review.

14.

[Approach to the treatment of intestinal infectious diseases caused by Clostridium difficile].

Nyc O.

Klin Mikrobiol Infekc Lek. 2010 Jun;16(3):93-6. Czech.

PMID:
20640987
15.

[Change of Clostridium difficile colitis during recent 10 years in Korea].

Lee YJ, Choi MG, Lim CH, Jung WR, Cho HS, Sung HY, Nam KW, Chang JH, Cho YK, Park JM, Kim SW, Chung IS.

Korean J Gastroenterol. 2010 Mar;55(3):169-74. Korean.

16.

Continuing diarrhoea after ten days of oral metronidazole or oral vancomycin for presumed, hospital-acquired Clostridium difficile colitis in elderly hospital patients.

Parks T, Wallis S, Wilson J, Gkrania-Klotsas E, Nicholl C.

J Hosp Infect. 2010 Apr;74(4):403-5. doi: 10.1016/j.jhin.2009.11.002. Epub 2010 Feb 12. No abstract available.

PMID:
20153080
17.

Glucocorticosteroids for primary sclerosing cholangitis.

Giljaca V, Poropat G, Stimac D, Gluud C.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004036. doi: 10.1002/14651858.CD004036.pub3. Review.

PMID:
20091555
18.

[Infections with Clostridium difficile following antibiotic therapy].

Scheppach W.

MMW Fortschr Med. 2009 Oct 1;151(40):47-9. Review. German. No abstract available.

PMID:
19927920
19.

Antibiotics for the treatment of primary sclerosing cholangitis.

Elfaki DA, Lindor KD.

Am J Ther. 2011 May;18(3):261-5. doi: 10.1097/MJT.0b013e3181b7b8c0. Review.

PMID:
19770792
20.

Clostridium difficile infection: historic review.

Bartlett JG.

Anaerobe. 2009 Dec;15(6):227-9. doi: 10.1016/j.anaerobe.2009.09.004. Epub 2009 Sep 12. No abstract available.

PMID:
19755167
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk